Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

About this update from Dyadic International, Inc.

New initiative builds on EN3ZYME™ launch and highlights scalability of the Dapibus™ platform JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food, nutrition, bio-industrial and biopharmaceutical markets, today announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program focused on advanced cellulose processing. The program builds on the successful commercialization of EN3ZYME™, Dyadic's first proprietary bio-industrial enzyme product developed in collaboration with Fermbox Bio and further demonstrates the repeatable product development capabilities of the Company's Dapibus™ platform. This propriety microbial expression system positions Dyadic to streamline development timelines, reduce manufacturing complexity, and potentially improve margins relative to traditional multi-strain systems, using a single microbial production strain. The newly developed enzyme is designed for applications such as pulp biorefining, microcrystalline cellulose and nanocellulose production. From a market perspective, the global industrial enzyme sector represents a multi-billion-dollar opportunity, with adoption accelerating as manufacturers seek cost-effective and environmentally sustainable alternatives to conventional chemical processes. Dyadic's focus on cellulose-related applications aligns with large, established end markets such as pulp and paper, while also providing exposure to higher-growth segments including second-generation renewable biofuels, biobased chemicals, biomaterials and specialty cellulose derivatives.    In addition to its specific product focus, the program highlights the versatility of the Dapibus™ platform in generating tailored application-specific enzyme solutions for proprietary use and strategic partnerships. Dyadic plans to pursue commercialization pathways, including direct product sales, collaborations, contract manufacturing, and technology licensing, creating diverse revenue opportunities. "We see this program as a key step in expanding our bio-industrial portfolio," said Joe Hazelton, President and Chief Operating Officer of Dyadic Applied BioSolutions. "Following the launch of EN3ZYME™, we continue to leverage the Dapibus™ platform to develop differentiated enzyme solutions for attractive industrial markets. Each new program further reinforces the scalability of the platform and strengthens our ability to drive value through proprietary products, strategic collaborations and licensing. Our goal is to build a diversified portfolio that supports long-term growth."

View stock analysis, news, and events for Dyadic International, Inc.